|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 November 2000, Vol. 96, No. 10, pp. 3302-3309
FOCUS ON HEMATOLOGY
Fibrinogen is an important determinant of the metastatic
potential of circulating tumor cells
Joseph S. Palumbo,
Keith W. Kombrinck,
Angela F. Drew,
Timothy S. Grimes,
John H. Kiser,
Jay L. Degen, and
Thomas H. Bugge
From the Divisions of Hematology/Oncology and
Developmental Biology, Children's Hospital Research Foundation and
University of Cincinnati College of Medicine, Cincinnati, OH.
Detailed studies of tumor cell-associated procoagulants and
fibrinolytic factors have implied that local thrombin generation and
fibrin deposition and dissolution may be important in tumor growth and
dissemination. To directly determine whether fibrin(ogen) or plasmin(ogen) are determinants of the metastatic potential of
circulating tumor cells, this study examined the impact of genetic
deficits in each of these key hemostatic factors on the hematogenous
pulmonary metastasis of 2 established murine tumors, Lewis lung
carcinoma and the B16-BL6 melanoma. In both tumor models, fibrinogen
deficiency strongly diminished, but did not prevent, the development of
lung metastasis. The quantitative reduction in metastasis in
fibrinogen-deficient mice was not due to any appreciable
difference in tumor stroma formation or tumor growth. Rather,
tumor cell fate studies indicated an important role for fibrin(ogen) in
sustained adhesion and survival of tumor cells within the lung. The
specific thrombin inhibitor, hirudin, further diminished the metastatic
potential of circulating tumor cells in fibrinogen-deficient mice,
although the inhibitor had no apparent effect on tumor cell
proliferation in vitro. The absence of plasminogen and plasmin-mediated
fibrinolysis had no significant impact on hematogenous
metastasis. The authors concluded that fibrin(ogen) is a critical
determinant of the metastatic potential of circulating tumor cells.
Furthermore, thrombin appears to facilitate tumor dissemination through
at least one fibrin(ogen)-independent mechanism. These findings suggest
that therapeutic strategies focusing on multiple distinct hemostatic
factors might be beneficial in the containment of tumor metastasis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. S. Alves, M. M. Burdick, S. N. Thomas, P. Pawar, and K. Konstantopoulos
The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion
Am J Physiol Cell Physiol,
April 1, 2008;
294(4):
C907 - C916.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Jackson, T. Hoshi, Y. Wu, X. Sun, K. Enjyoji, E. Cszimadia, C. Sundberg, and S. C. Robson
Disordered Purinergic Signaling Inhibits Pathological Angiogenesis in Cd39/Entpd1-Null Mice
Am. J. Pathol.,
October 1, 2007;
171(4):
1395 - 1404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-S. Wang, C.-Y. Chang, S.-E. Chow, Y.-W. Chen, and C.-M. Yang
Exercise modulates platelet-nasopharyngeal carcinoma cell aggregation and subsequent tissue factor and matrix metalloproteinase activities
J Appl Physiol,
September 1, 2007;
103(3):
763 - 770.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, Z. Hu, K. A. Barney, and J. L. Degen
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms
Blood,
July 1, 2007;
110(1):
133 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jain, M. Zuka, J. Liu, S. Russell, J. Dent, J. A. Guerrero, J. Forsyth, B. Maruszak, T. K. Gartner, B. Felding-Habermann, et al.
Platelet glycoprotein Ib{alpha} supports experimental lung metastasis
PNAS,
May 22, 2007;
104(21):
9024 - 9028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Arora, T. K. Ricks, and J. Trejo
Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer
J. Cell Sci.,
March 15, 2007;
120(6):
921 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Ghajar, V. Suresh, S. R. Peyton, C. B. Raub, F. L. Meyskens Jr., S. C. George, and A. J. Putnam
A novel three-dimensional model to quantify metastatic melanoma invasion
Mol. Cancer Ther.,
February 1, 2007;
6(2):
552 - 561.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Matsuo, S. Amano, M. Furuya, K. Namiki, K. Sakurai, M. Nishiyama, T. Sudo, K. Tatsumi, T. Kuriyama, S. Kimura, et al.
Involvement of p38{alpha} Mitogen-activated Protein Kinase in Lung Metastasis of Tumor Cells
J. Biol. Chem.,
December 1, 2006;
281(48):
36767 - 36775.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pilch, D. M. Brown, M. Komatsu, T. A. H. Jarvinen, M. Yang, D. Peters, R. M. Hoffman, and E. Ruoslahti
Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds
PNAS,
February 21, 2006;
103(8):
2800 - 2804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana, C. W. Francis, E. Culakova, R. I. Fisher, N. M. Kuderer, and G. H. Lyman
Thromboembolism in Hospitalized Neutropenic Cancer Patients
J. Clin. Oncol.,
January 20, 2006;
24(3):
484 - 490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Morris, Y. Ding, T. K. Ricks, A. Gullapalli, B. L. Wolfe, and J. Trejo
Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells
Cancer Res.,
January 1, 2006;
66(1):
307 - 314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sahni, A. A. Khorana, R. B. Baggs, H. Peng, and C. W. Francis
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
Blood,
January 1, 2006;
107(1):
126 - 131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.-J. Cheng, L.-C. Chen, K.-Y. Chien, Y.-J. Chen, J. T.-C. Chang, H.-M. Wang, C.-T. Liao, and I-H. Chen
Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology
Clin. Chem.,
December 1, 2005;
51(12):
2236 - 2244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yamashita, J. Kitayama, and H. Nagawa
Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer
Jpn. J. Clin. Oncol.,
October 1, 2005;
35(10):
595 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Stevenson, S. H. Choi, and A. Varki
Differential Metastasis Inhibition by Clinically Relevant Levels of Heparins--Correlation with Selectin Inhibition, Not Antithrombotic Activity
Clin. Cancer Res.,
October 1, 2005;
11(19):
7003 - 7011.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Belting, J. Ahamed, and W. Ruf
Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2005;
25(8):
1545 - 1550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kockar, O. Kockar, M. Ozturk, M. Dagli, N. Bavbek, and A. Kosar
Global Fibrinolytic Capacity Increased Exponentially in Metastatic Colorectal Cancer
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2005;
11(2):
227 - 230.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, M. Jirouskova, and J. L. Degen
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
Blood,
January 1, 2005;
105(1):
178 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Im, W. Fu, H. Wang, S. K. Bhatia, D. A. Hammer, M. A. Kowalska, and R. J. Muschel
Coagulation Facilitates Tumor Cell Spreading in the Pulmonary Vasculature during Early Metastatic Colony Formation
Cancer Res.,
December 1, 2004;
64(23):
8613 - 8619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dorfleutner, E. Hintermann, T. Tarui, Y. Takada, and W. Ruf
Cross-talk of Integrin {alpha}3{beta}1 and Tissue Factor in Cell Migration
Mol. Biol. Cell,
October 1, 2004;
15(10):
4416 - 4425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Georgakoudi, N. Solban, J. Novak, W. L. Rice, X. Wei, T. Hasan, and C. P. Lin
In Vivo Flow Cytometry: A New Method for Enumerating Circulating Cancer Cells
Cancer Res.,
August 1, 2004;
64(15):
5044 - 5047.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Camerer, A. A. Qazi, D. N. Duong, I. Cornelissen, R. Advincula, and S. R. Coughlin
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis
Blood,
July 15, 2004;
104(2):
397 - 401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, and B. M. Mueller
Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis
Mol. Cancer Res.,
July 1, 2004;
2(7):
395 - 402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Hembrough, J. F. Ruiz, B. M. Swerdlow, G. M. Swartz, H. J. Hammers, L. Zhang, S. M. Plum, M. S. Williams, D. K. Strickland, and V. S. Pribluda
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity
Blood,
May 1, 2004;
103(9):
3374 - 3380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Booden, L. B. Eckert, C. J. Der, and J. Trejo
Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion
Mol. Cell. Biol.,
March 1, 2004;
24(5):
1990 - 1999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Palumbo, K. E. Talmage, H. Liu, C. M. La Jeunesse, D. P. Witte, and J. L. Degen
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency
Blood,
October 15, 2003;
102(8):
2819 - 2827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H Reinhart
Fibrinogen - marker or mediator of vascular disease?
Vascular Medicine,
August 1, 2003;
8(3):
211 - 216.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Hembrough, G. M. Swartz, A. Papathanassiu, G. P. Vlasuk, W. E. Rote, S. J. Green, and V. S. Pribluda
Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism
Cancer Res.,
June 1, 2003;
63(11):
2997 - 3000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ozturk, N. Sengul, M. Dagli, A. Kosar, and N. Bavbek
Global Fibrinolytic Capacity in Colorectal Cancer: A New Clue to Occult Fibrinolysis
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2003;
9(2):
151 - 154.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Palumbo, J. M. Potter, L. S. Kaplan, K. Talmage, D. G. Jackson, and J. L. Degen
Spontaneous Hematogenous and Lymphatic Metastasis, but not Primary Tumor Growth or Angiogenesis, Is Diminished in Fibrinogen-deficient Mice
Cancer Res.,
December 1, 2002;
62(23):
6966 - 6972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pilch, R. Habermann, and B. Felding-Habermann
Unique Ability of Integrin alpha vbeta 3 to Support Tumor Cell Arrest under Dynamic Flow Conditions
J. Biol. Chem.,
June 7, 2002;
277(24):
21930 - 21938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Drew, H. Liu, J. M. Davidson, C. C. Daugherty, and J. L. Degen
Wound-healing defects in mice lacking fibrinogen
Blood,
June 15, 2001;
97(12):
3691 - 3698.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|